A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema - 24/08/11
Doi : 10.1016/j.jaad.2004.03.023
Keren B Horn, MD a, Meyer A Horn, MD c, James Swan, MD a, Seema Singhal, MD b, Joan Guitart, MD a, ⁎ 
From the Departments of Dermatology,a and Hematology/Oncology,b Feinberg School of Medicine, Northwestern University, and the Northwestern Memorial Physicians Group, Northwestern Memorial Hospitalc USA
Correspondence to: Joan Guitart, MD, 675 N St. Clair St, Suite 19-150, Chicago, IL 60611.Chicago, Illinois
Abstract |
We report a case of a patient with scleromyxedema limited to the skin with an associated IgG λ monoclonal protein treated successfully with high-dose dexamethasone. We encourage the continued investigation of this complex relationship between the clinical presentation of scleromyxedema and its frequently associated paraproteinemia.
Le texte complet de cet article est disponible en PDF.Plan
 | This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology. Funding sources: None. Conflicts of interest: None identified. Reprints not available from authors. |
© 2004
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 51 - N° 2S
P. 120-123 - août 2004 Retour au numéro
Article précédent
- Idiopathic calcinosis cutis of the penis
- José María Sánchez-Merino, Marta Bouso-Montero, Angel Fernández-Flores, Jesús García-Alonso
- Self-resolution of Epstein-Barr virus–associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate
- Mark A Waldman, Jeffrey P Callen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?